Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dna X (SONM) Research & Development (2018 - 2025)

Dna X filings provide 8 years of Research & Development readings, the most recent being $181000.0 for Q3 2025.

  • On a quarterly basis, Research & Development fell 74.69% to $181000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $15.2 million, a 473.85% increase, with the full-year FY2024 number at $14.2 million, up 703.33% from a year prior.
  • Research & Development hit $181000.0 in Q3 2025 for Dna X, down from $909000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $12.5 million in Q4 2024 to a low of -$135000.0 in Q3 2022.
  • Median Research & Development over the past 5 years was $1.1 million (2022), compared with a mean of $2.5 million.
  • Biggest five-year swings in Research & Development: tumbled 102.46% in 2022 and later skyrocketed 1250.65% in 2024.
  • Dna X's Research & Development stood at $3.9 million in 2021, then plummeted by 68.5% to $1.2 million in 2022, then fell by 24.04% to $926000.0 in 2023, then skyrocketed by 1250.65% to $12.5 million in 2024, then plummeted by 98.55% to $181000.0 in 2025.
  • The last three reported values for Research & Development were $181000.0 (Q3 2025), $909000.0 (Q2 2025), and $1.6 million (Q1 2025) per Business Quant data.